VcMMAE-d8

• UNSPSC Description:

  VcMMAE-d8 is an isotope of VcMMAE (HY-15575). VcMMAE-d8 is a agent-linker conjugate for ADC with potent antitumor activity by using the anti-mitotic agent, monomethyl auristatin E (MMAE, a tubulin inhibitor), linked via the lysosomally cleavable dipeptide, valine-citrulline (vc)[1].

• Target Antigen:

  Drug-Linker Conjugates for ADC; Microtubule/Tubulin

• Type:

  Isotope-Labeled Compounds

• Related Pathways:

  Antibody-drug Conjugate/ADC Related;Cell Cycle/DNA Damage;Cytoskeleton

• Applications:

  Cancer-programmed cell death

• Field of Research:

  Cancer

• Purity:

  97.56

• Solubility:

  10 mM in DMSO

• Smiles:

  CC([C@H](NC(CCCCCN1C(C=CC1=O)=O)=O)C(N[C@H](C(NC2=CC=C(C=C2)COC(N([C@H](C(N[C@@]([2H])(C(C([2H])([2H])[2H])(C([2H])([2H])[2H])[2H])C(N([C@H]([C@@H](CC(N3[C@@H](CCC3)[C@@H]([C@H](C(N[C@@H]([C@@H](O)C4=CC=CC=C4)C)=O)C)OC)=O)OC)[C@H](CC)C)C)=O)=O)C(C)C)C)=O)=O)CCCNC(N)=O)=O)C

• Molecular Weight:

  1324.68

• References & Citations:

  [1]Okeley, et al. Intracellular Activation of SGN-35, a Potent Anti-CD30 Antibody-Drug Conjugate. Clinical Cancer Research (2010), 16(3), 888-897.

• Shipping Conditions:

  Blue Ice

• Storage Conditions:

  -20°C (Powder, sealed storage, away from moisture)

• Clinical Information:

  No Development Reported